首页|重组人粒细胞刺激因子联合化疗治疗急性白血病的疗效分析

重组人粒细胞刺激因子联合化疗治疗急性白血病的疗效分析

扫码查看
目的 分析重组人粒细胞刺激因子联合化疗药物治疗急性白血病的临床疗效.方法 选取60例急性白血病患者为研究对象(2015年2月~2017年4月收治).对照组给予常规化疗,实验组在此基础上给予重组人粒细胞刺激因子治疗.比较分析2组患者相关临床指标.结果 经过对应的治疗后,实验组治疗有效率为63.3%,对照组治疗有效率为43.3%,差异具有统计学意义(P<0.05).治疗后,对照组生活质量评分为(62.30±9.20)显著低于实验组评分(76.88±10.90)分,差异具有统计学意义(P<0.05).实验组中性粒从0.1×109/L到1.5×109/L需要时间为(11.23±1.65)d,对照组需要(18.90±2.78)d,2组差异具有统计学意义(P<0.05).2组患者均未出现严重的不良反应,发生率分别为10.0%与13.3%,不具有统计学意义.结论 重组人粒细胞刺激因子联合化疗药物治疗急性白血病临床疗效较为理想.
Effects analysis of rhG-CSF combined with chemotherapy in the treatment of acute leukemia
Objective To study and analyze the clinical effects of rhG-CSF combined with chemotherapy in the treatment of acute leukemia. Methods 60 patients with acute leukemia were selected as the study subjects (from February 2015 to April 2017). The control group was given routine chemotherapy, the experimental group was given rhG-CSF on the basis treatment of the control group. Clinical indicators of two groups of patients were compared and analyzed. Results After the corresponding treatment, the effective rate was 63.3% in the experimental group and 43.3% in the control group, and the difference was statistically significant (P<0.05). After treatment, the quality of life score of the control group (62.30±9.20) was significantly lower than the experimental group (76.88±10.90) with statistical difference (P<0.05). The number of neutrophils reduced from 0.1×109/L to 1.5×109/L in the experimental group took (11.23±1.65), and the time for the control group was (18.90±2.78), and the difference between the two groups was statistically significant (P<0.05). There were no serious adverse reactions in the two groups, and the incidence was 10% and 13.3%, which was not statistically significant. Conclusion rhG-CSF combined with chemotherapy in the treatment of acute leukemia has good clinical effect.

rhG-CSFchemotherapyacute leukemia

吴振波、张秀华

展开 >

温州医科大学附属第五医院 药学部,浙江 丽水 323000

温州医科大学附属第一医院 药学部,浙江 温州 325000

重组人粒细胞刺激因子 化疗药物 急性白血病

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(10)
  • 1
  • 6